Additionally, it was observed that the HIF1α inhibitor (BAY87-2243) inhibited the growth of subcutaneous tumors constructed by FSTL3-OE MC38 cells, suggesting the potentially value of BAY87-2243 for CRC patients with high FSTL3 expression (Supplementary Fig. S8D–F). This evidence concerns the gene FSTL3 and colorectal carcinoma.